A complaint filed this week urges the state of Arkansas to defend a pharmaceutical manufacturer accountable for violating a first-of-its-kind state law.

Starting in the summer of 2020, pharmaceutical manufacturers placed multiple restrictions on contract pharmacies under the 340B program, a complaint filed this week urges the state of Arkansas to hold a pharmaceutical manufacturer accountable for violating a first-of-its-kind state law.

In September 2021, in U.S. District Court in Little Rock, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit against the Insurance Department to enforce its rule. We wholeheartedly agree that Act 1103 is constitutional and sound public policy.(

A complaint filed this week urges the state of Arkansas to hold a pharmaceutical manufacturer accountable for violating a first-of-its-kind state law.

In September 2021, in U.S. District Court in Little Rock, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit against the Insurance Department to enforce its rule. We wholeheartedly agree that Act 1103 is constitutional and sound public policy.

In September 2021, in U.S. District Court in Little Rock, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit against the Insurance Department to enforce its rule. We wholeheartedly agree that Act 1103 is constitutional and sound public policy.

In September 2021, in U.S. District Court in Little Rock, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit against the Insurance Department to enforce its rule. We wholeheartedly agree that Act 1103 is constitutional and sound public policy.

In September 2021, in U.S. District Court in Little Rock, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit against the Insurance Department to enforce its rule. We wholeheartedly agree that Act 1103 is constitutional and sound public policy.